Inovio Pharmaceuticals (INO) PT Set at $13.00 by HC Wainwright
Inovio Pharmaceuticals (NASDAQ:INO) has been given a $13.00 price target by analysts at HC Wainwright in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 189.53% from the company’s current price.
INO has been the subject of several other research reports. Citigroup initiated coverage on Inovio Pharmaceuticals in a research report on Friday, October 6th. They set a “buy” rating and a $10.00 price target for the company. BidaskClub downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. ValuEngine raised Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 11th. Royal Bank Of Canada initiated coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target for the company. Finally, Zacks Investment Research downgraded Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $19.16.
Inovio Pharmaceuticals (INO) opened at $4.49 on Tuesday. Inovio Pharmaceuticals has a 1 year low of $4.20 and a 1 year high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The business’s quarterly revenue was down 79.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.28) EPS. sell-side analysts anticipate that Inovio Pharmaceuticals will post -1.12 EPS for the current year.
Large investors have recently made changes to their positions in the company. BlueCrest Capital Management Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter valued at $107,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $101,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $115,000. Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at $117,000. Finally, Emerald Advisers Inc. PA grew its position in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 9,280 shares during the period. 32.29% of the stock is owned by institutional investors and hedge funds.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.